Skip to content

A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03057171
Enrollment
50
Registered
2017-02-17
Start date
2015-05-31
Completion date
2020-04-30
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duodenal Ulcer, Gastric Ulcer, Helicobacter Pylori Infection, Stomach Cancer

Keywords

Helicobacter pylori, long non-coding RNA, THRIL, PACER, cagA

Brief summary

Helicobacter pylori (H.pylori) is a major human pathogenic bacterium in gastric mucosa which is linked to the development of gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. However the regulatory mechanism of H.pylori-induced immune response is not clear. Long non-coding RNA (lncRNA) has recently emerged as key post-transcriptional regulators of gene expression, differentiation. The investigators had a preliminary results which THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) and PACER(p50-associated COX-2 extragenic RNA) played a potential role in H.pylori induced inflammatory cascade. However, there wasn't a previous study about expression of THRIL, PACER in a human tissue. Therefore, the investigators aimed to evaluate the expression of THRIL, PACER in patients with gastrointestinal disease according to H.pylori infection.

Interventions

None listed

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Over 19 years old 2. Patients with gastric ulcer 3. Patients with duodenal ulcer 4. Patients with stomach cancer 5. Patients with gastrointestinal discomfort symptoms

Exclusion criteria

1. Patients who has done helicobacter pylori eradication 2. Patients who has undergone gastrectomy 3. Patients who has undergone endoscopic submucosal dissection 4. Patients with active upper gastrointestinal bleeding

Design outcomes

Primary

MeasureTime frameDescription
Expression of THRIL, PACERWithin 2 weeks after EGDExpression of THRIL, PACER according to Helicobacter pylori infection by Real-time aRT-PCR

Countries

South Korea

Contacts

Primary ContactSang Kil Lee, MD
sklee@yuhs.ac82-2-2228-1996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026